Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
lotilaner · 1 trial · 1 indication
Number of patients with treatment related emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Treatment arm | EXPERIMENTAL | lotilaner - high dose and low dose |
| Control arm | OTHER | Vehicle of lotilaner - high dose and low dose |
| Name | Type | Description |
|---|---|---|
| lotilaner | DRUG | lotilaner |
| Vehicle | DRUG | Vehicle of lotilaner |
Inclusion Criteria: * 18 years of age or older at the time of consent. * Has moderate to severe ocular rosacea * Use of acceptable methods of contraception * Are willing to sign the informed consent form and is deemed capable of complying with the requirements of the study protocol Exclusion Crite...
Lotilaner, 2.0% is an investigational small molecule being studied for the treatment of ocular rosacea and papulopustular rosacea. It is developed by Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS). The drug is currently in Phase 2 clinical development for these dermatological conditions.
Lotilaner, 2.0% is a small molecule that targets and inhibits parasite-specific GABA-gated chloride channels, leading to paralysis and death of parasites. This mechanism is being evaluated for its potential to treat rosacea by addressing underlying parasitic factors. The drug is administered topically as an ophthalmic gel or other formulation.
Lotilaner, 2.0% is being developed by Tarsus Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol TARS. Tarsus is conducting clinical trials to evaluate the drug's safety and efficacy for treating ocular rosacea and papulopustular rosacea.
Lotilaner, 2.0% is in Phase 2 clinical development. It is not FDA approved and remains investigational. Two Phase 2 trials have been conducted or are ongoing: one completed study in papulopustular rosacea and another enrolling study in ocular rosacea.
Lotilaner, 2.0% is being studied in two Phase 2 trials. NCT05838170, a completed study in papulopustular rosacea with 37 participants in Canada, and NCT07443202, an enrolling study in ocular rosacea with 155 participants in the United States. Both are randomized, double-blind, placebo-controlled trials.
Yes, Lotilaner, 2.0% is the same drug as lotilaner. The 2.0% refers to the concentration of the active ingredient in the formulation being studied. Lotilaner is the generic name for this small molecule compound developed by Tarsus Pharmaceuticals.